T4	iv-cont-median 914 925	22.7 months
T5	cv-cont-median 951 962	22.4 months
T7	iv-cont-median 798 801	9.8
T8	cv-cont-median 806 816	6.5 months
T9	outcome 654 675	overall response rate
T10	iv-bin-percent 680 684	62.5
T11	cv-bin-percent 689 694	42.6%
T12	intervention-participants 460 465	Fifty
T13	control-participants 540 542	51
T15	control 570 613	paclitaxel 175 mg/m2 and cisplatin 50 mg/m2
T17	total-participants 336 339	101
T18	eligibility 340 443	patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane
T16	intervention 35 56	taxanes and cisplatin
T2	outcome 1105 1114	mucositis
T14	outcome 1116 1123	fatigue
T19	outcome 1128 1139	neutropenia
T1	outcome 1039 1045	anemia
T20	outcome 1016 1034	sensory neuropathy
T21	outcome 986 1014	Grade 3/4 arthralgia/myalgia
T6	outcome 759 793	Median time to disease progression
T3	outcome 881 909	median overall survival time
